Development of sclerosing cholangitis during long-term interferon-alpha-2b therapy.
Meuthen
I
I
Clinic of Medicine, Cologne City Clinic, Holweide Hospital, Germany.
Böhcken
L
L
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy; D002760:Cholangiopancreatography, Endoscopic Retrograde; D015209:Cholangitis, Sclerosing / Q000000981:diagnostic imaging / Q000209:etiology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013997:Time Factors
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins